Ulcers on the bilateral palate mucosa following mRNA-based vaccination for coronavirus disease 2019 (COVID-19): A case report

Maeda, Keigo; Yamashita, Daisuke; Takenobu, Toshihiko

doi:10.1016/j.jormas.2022.01.013

Cited by 8 publications

(10 citation statements)

References 12 publications

(19 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Five additional records [ 18 , 19 , 20 , 21 , 22 ], manually retrieved through the reference lists of the eight articles already included in the present systematic review [ 9 , 23 , 24 , 25 , 26 , 27 , 28 , 29 ] and compliant with currently applied eligibility criteria were considered for the current systematic review.…”

Section: Resultsmentioning

confidence: 99%

“…Comorbidities and related treatments, reported in 5 cases, were: Leiden factor V mutation in a 31 year old female taking oral contraceptives [ 18 ]; diabetes mellitus and hypertension, treated with amlodipine, teneligliptin, and metformin in a 60-year-old male [ 20 ]; benign pemphigoid of mucous membranes [ 29 ] and celiac disease [ 29 ] in a 55- and a 20-year-old female, respectively; and a 58-year-old female, under sertraline, lorazepam, atorvastatin, metamizole, and penicillin [ 9 ]. Eight participants had a negative history of COVID-19 [ 9 , 18 , 21 , 25 , 29 ], while in one case, the subject became positive for SARS-CoV-2 in the time between the first and second vaccine dose [ 23 ]; in the remaining 7 cases, the previous history of COVID-19 was not specified [ 19 , 20 , 21 , 22 , 24 , 26 , 27 , 28 ].…”

Section: Resultsmentioning

confidence: 99%

“…Out of the 16 cases diagnosed with oral lesions following anti-SARS-CoV-2 vaccination, 9 cases were diagnosed with oral lesions following the administration of the Pfizer-BioNTech vaccine [ 19 , 24 , 25 , 26 , 28 , 29 ], 2 cases after vaccination with the Moderna vaccine [ 9 , 27 ], and 1 case was described after AstraZeneca [ 18 ], Serum Institute of India [ 20 ], Sinopharm Beijing [ 23 ], and Johnson & Johnson [ 22 ] vaccines, respectively. Oral lesions occurred consequent to the single dose of the Johnson & Johnson vaccine in one case [ 22 ], after the administration of the first dose in a total of 8 cases (5 after the Pfizer-BioNTech [ 19 , 26 , 28 , 29 ], and 1 after the AstraZeneca [ 18 ], Serum Institute of India [ 20 ], and Sinopharm Beijing [ 23 ] vaccines, respectively) and in 7 cases after the administration of thesecond dose (4 after the Pfizer-BioNTech, 2 after Moderna, and 1 after Sinopharm Beijing vaccines, respectively) [ 9 , 24 , 25 , 26 , 27 , 29 ]. In one case [ 21 ], data concerning vaccine type and dose were missing.…”

Section: Resultsmentioning

confidence: 99%

See 2 more Smart Citations

Oral Lesions Following Anti-SARS-CoV-2 Vaccination: A Systematic Review

Spirito

Amato

Palo

et al. 2022

IJERPH

View full text Add to dashboard Cite

Increasing evidence relate anti-SARS-CoV-2 vaccinations to orofacial adverse reactions, therefore, the present systematic review aimed to evaluate primary oral lesions diagnosed in adult subjects, following the WHO Emergency Use Listing approved and EMA authorized vaccines, also in relation to cases’ age, gender, comorbidities, and history of COVID-19, and in relation to vaccine type and doses. The study protocol, registered on PROSPERO (CRD42022339032) and compliant with the PRISMA statement, included an electronic search across Scopus, MEDLINE/PubMed, BioMed Central databases, and PROSPERO, ended on 18 June 2022 and succeeded by a manual search, an independent data extraction, and arisk of bias evaluation through ROBINS-I tool. Qualitatively synthesized data from the 13studies included showed an overall low prevalence (16 cases), though higher in females (68.8%), of oral lesions, mainly erosions and ulcers (34.5%). Nine cases were diagnosed following Pfizer-BioNTech, two Moderna, and one AstraZeneca, Serum Institute of India, Sinopharm, and Johnson&Johnson vaccines, respectively; specifically, eight after the first dose and seven after the second. In one case, vaccine type and dose were not specified. Considering newly developing vaccines, presented findings may be updated and further studies needed to highlight factors affecting oral lesion occurrence and specific macro-microscopic phenotypes in relation to cases’ and vaccines’ characteristics.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Oral Lesions Following Anti-SARS-CoV-2 Vaccination: A Systematic Review

Spirito

Amato

Palo

et al. 2022

IJERPH

View full text Add to dashboard Cite

show abstract

“…Aphthous stomatitis was suspected to be linked with recent COVID-19 vaccination in a few reported cases where patients presented with non-specific oral ulcers ( 39 , 40 ). Unlike oral herpes, the prevalence of aphthous stomatitis was not significantly higher among COVID-19 vaccinees (0.168 vs. 0.158%; Sig .…”

Section: Discussionmentioning

confidence: 99%

Oral Adverse Events Following COVID-19 Vaccination: Analysis of VAERS Reports

Riad

Põld

Kateeb

et al. 2022

Front. Public Health

View full text Add to dashboard Cite

BackgroundOral adverse events (AEs) following COVID-19 vaccination have been sporadically reported during the previous months, warranting further investigation for their prevalence and suspected relationship with vaccine-elicited immune response.MethodsA retrospective analysis using the Vaccine Adverse Event Reporting System (VAERS) data was conducted to evaluate AEs within the oral cavity (mucosa, tongue, lips, palate, dentition, salivary glands) and AEs involving taste and other sensations. Oral AEs reported after receiving COVID-19 vaccination (test group) and seasonal influenza vaccination (control group) were extracted and cross-tabulated to assess their relative prevalence.ResultsAmong the 128 solicited (suspected) oral AEs, oral paresthesia (0.872%) was most reported after receiving COVID-19 vaccines, followed by the swelling of lips (0.844%), ageusia (0.722%), oral hypoesthesia (0.648%), swollen tongue (0.628%), and dysgeusia (0.617%). The reported prevalence of oral AEs was higher in the COVID-19 vaccine group than in the seasonal influenza group. The distribution pattern of the most reported oral AEs was similar for both COVID-19 and seasonal influenza vaccines. Female sex, older age (>39 years old), primer doses, and mRNA-based COVID-19 vaccines exhibited a higher reported prevalence of oral AEs.ConclusionWithin the limitations of this study, COVID-19 vaccines were found to be associated with rare oral AEs that are predominantly similar to those emerging following seasonal influenza vaccines. The most commonly reported oral AEs were oral paraesthesia (mouth-tingling), lip swelling, and ageusia, representing various pathophysiologic pathways that remain unclear. Taste-related AEs should be acknowledged in the context of the COVID-19 pandemic and the public should be adequately informed about a potential taste dysfunction after receiving the COVID-19 vaccination. Dentists and dental teams need to be aware of the prevalence, severity, and prognosis of oral AEs to inform their patients and increase public confidence in vaccines.

show abstract

“…Manfredi et al reported a case of multiple painful oral ulcers that developed a few days after the first dose of the BNT162b2 vaccine administration [ 39 ]. Maeda et al presented another case of extensive palatal ulcers that emerged 10 days after the second dose of the mRNA-1273 COVID-19 vaccine injection [ 40 ]. The lesions from both mentioned cases had a self-limited character, and complete resolution was reported after topical or systemic treatment.…”

Section: Discussionmentioning

confidence: 99%

Hematologic Malignancies Diagnosed in the Context of the mRNA COVID-19 Vaccination Campaign: A Report of Two Cases

Zamfir¹,

Moraru

Dobrea

et al. 2022

Medicina

View full text Add to dashboard Cite

Background: During the last two years, the COVID-19 pandemic led to millions of disease-related deaths worldwide. The efforts of the scientific community facing this global challenge resulted in outstanding achievements. Thus, within one year, new mRNA-based vaccines against SARS-CoV-2 viral infection were released, providing highly efficient protection and showing a very good safety profile in the general population. However, clinical data collection after vaccination is a continuous process for the long-term safety of any new medical product. The aim of our paper is to present two cases of hematological malignancies: diffuse large B-cell non-Hodgkin lymphoma and T/NK-cell lymphoma, diagnosed shortly after the administration of the mRNA COVID-19 vaccine. Methods and Results: Case 1: A female patient was admitted with a suspicious cervical mass that emerged within one week after the administration of second dose of the BNT162b2 COVID-19 vaccine. Surgical removal followed by pathology assessment of the specimen confirmed the diagnosis of diffuse large B-cell non-Hodgkin lymphoma. Case 2: A male patient was admitted with multiple ulcerative oral lesions arising on the third day after the initial dose of the BNT162b2 COVID-19 vaccine. These lesions had a progressive character and during the following months were complicated with repetitive episodes of heavy oral bleeding, requiring blood transfusions. The incisional biopsy of the lesions and pathological assessment of the specimens confirmed the diagnosis of T/NK-cell lymphoma. Conclusions: The safety profile of the mRNA-based vaccines is an undeniable fact. In most cases, suspicions of potentially aggressive side effects were ruled out, proving to be transient post-vaccine reactions. Clinicians should remain alert to report any potentially aggressive manifestations emerging in the context of mRNA COVID-19 vaccination, such as these cases of hematological malignancies, in order to promote additional investigations on the particular mechanisms of action of COVID-19 vaccines and to provide the best medical care to the patients.

show abstract

Ulcers on the bilateral palate mucosa following mRNA-based vaccination for coronavirus disease 2019 (COVID-19): A case report

Cited by 8 publications

References 12 publications

Oral Lesions Following Anti-SARS-CoV-2 Vaccination: A Systematic Review

Oral Lesions Following Anti-SARS-CoV-2 Vaccination: A Systematic Review

Oral Adverse Events Following COVID-19 Vaccination: Analysis of VAERS Reports

Hematologic Malignancies Diagnosed in the Context of the mRNA COVID-19 Vaccination Campaign: A Report of Two Cases

Contact Info

Product

Resources

About